%PDF-1.4
%
58 0 obj
<>
endobj
55 0 obj
<>
endobj
121 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T11:16:17Z
2024-03-28T12:34:03-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T12:34:03-07:00
application/pdf
Heather
2001-552.june
uuid:a3042395-1dd1-11b2-0a00-e90827fd5800
uuid:a3042398-1dd1-11b2-0a00-6a0000000000
endstream
endobj
44 0 obj
<>
endobj
45 0 obj
<>
endobj
59 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
31 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
40 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
159 0 obj
[163 0 R]
endobj
160 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 9.7 0 0 10 54 713.1616 Tm
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc 0.02521 Tw 7.76 0 0 8 54 703.1616 Tm
(The authors thank Drs. Matthew H. Liang and John M. Esdaile for their cr\
it-)Tj
0.02499 Tw 0 -1.25 TD
(ical review of the manuscript.)Tj
/TT0 1 Tf
-0.00011 Tc 0 Tw 9.7 0 0 10 54 669.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 61 659.1616 Tm
[(1.)-875.1 (Kremer JM. Methotrexate and emer)17.7 (ging therapies. Rheum Dis Clin)]TJ
0 Tc -0.02991 Tw 1.675 -1.25 Td
[(North Am )-54.9 (1998;24:651-8.)]TJ
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Smolen JS, Kalden JR, Scott DL, et al. Ef)17.8 (ficacy and safety of)]TJ
1.675 -1.25 Td
(leflunomide compared with placebo and sulphasalazine in active)Tj
T*
(rheumatoid arthritis: a double-blind, randomised, multicentre trial.)Tj
T*
(Lancet 1999;353:259-66.)Tj
-1.675 -1.25 Td
[(3.)-875 (Strand )17.8 (V)129.1 (, Cohen S, Schif)17.8 (f M, et al. )17.8 (T)34.9 (reatment of active rheumatoid)]TJ
1.675 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
T*
(Arch Intern Med 1999;159:2542-50.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Bathon JM, Martin R)54.8 (W)91.7 (, Fleischmann RM, et al. )54.8 (A)-219.9 (comparison of)]TJ
0 Tc 1.675 -1.25 Td
(etanercept and methotrexate inpatients with early rheumatoid)Tj
T*
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (W)79.7 (einblatt ME, Kremer JM, Bankhurst )54.8 (AD, et al. )54.8 (A)-219.9 (trial of)]TJ
0 Tc 1.675 -1.25 Td
(etanercept, a recombinant tumor necrosis factor receptor:Fc fusion)Tj
T*
(protein, in patients with rheumatoid arthritis receiving)Tj
T*
(methotrexate. N Engl J Med 1999;340:253-9.)Tj
-1.675 -1.25 Td
[(6.)-875 (T)34.9 (ugwell P)110.8 (,)0.1 ( Pincus )17.7 (T)74 (, )36.8 (Y)100.1 (ocum D, et al. Combination therapy with)]TJ
1.675 -1.25 Td
[(cyclosporine and methotrexate in severe rheumatoid arthritis. )17.8 (The)]TJ
T*
(Methotrexate-Cyclosporine Combination Study Group. N Engl J)Tj
T*
(Med 1995;333:137-41.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Choi HK, Seeger JD, Kuntz KM. )54.8 (A)-219.9 (cost ef)17.7 (fectiveness analysis of)]TJ
0 Tc 1.675 -1.25 Td
(treatment options for patients with methotrexate-resistant)Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 2000;43:2316-27.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
0 Tc 1.675 -1.25 Td
[(Rheumatology)64.9 (. Preliminary definition of improvement in)]TJ
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1995;38:727-35.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Kavanaugh )54.9 (A, Heudebert G, Cush J, Jain R. Cost evaluation of)]TJ
1.675 -1.25 Td
(novel therapeutics in rheumatoid arthritis \(CENTRA\): a decision)Tj
T*
[(analysis model. Semin )54.9 (Arthritis Rheum 1996;25:297-307.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Emery P)110.8 (, Breedveld FC, Lemmel EM, et al. )54.8 (A)-219.8 (comparison of the)]TJ
2.175 -1.25 Td
[(ef)17.8 (ficacy and safety of leflunomide and methotrexate for the)]TJ
T*
(treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.)Tj
-0.00011 Tc 30.8619 45.671 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Moreland L)73.9 (W)91.7 (, Schif)17.7 (f MH, Baumgartner SW)91.7 (, et al. Etanercept)]TJ
0 Tc 2.1381 -1.25 Td
[(therapy in rheumatoid arthritis. )54.9 (A)-219.8 (randomized, controlled trial. )54.9 (Ann)]TJ
T*
(Intern Med 1999;130:478-86.)Tj
-2.175 -1.25 Td
[(12.)-875 (Medical Economics Company)64.9 (. Red Book. Montvale \(NJ\): Medical)]TJ
2.175 -1.25 Td
(Economics Company; 1999.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Prashker MJ, Meenan RF)79.7 (. )17.7 (The total costs of drug therapy for)]TJ
0 Tc 2.175 -1.25 Td
[(rheumatoid arthritis. )54.9 (A)-219.8 (model based on costs of drug, monitoring,)]TJ
T*
[(and toxicity)64.9 (. )54.9 (Arthritis Rheum 1995;38:318-25.)]TJ
-2.175 -1.25 Td
[(14.)-875 (American College of Rheumatology )54.9 (Ad Hoc Committee on Clinical)]TJ
2.175 -1.25 Td
(Guidelines: Guideline for monitoring drug therapy in rheumatoid)Tj
T*
[(arthritis. )54.9 (Arthritis Rheum 1996;39:723-31.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Smith SL. Medicare RBR)79.8 (VS. )17.8 (The physician\222)54.9 (s guide: )54.9 (American)]TJ
-0.02991 Tw 2.175 -1.25 Td
[(Medical Association; )-54.9 (1999.)]TJ
-0.00011 Tc 0.0249 Tw -2.175 -1.25 Td
[(16.)-875.1 (Haddix )54.7 (AC, )17.6 (T)69.7 (eutsch SM, Shaf)17.7 (fer P)91.7 (A, Dunet DO. Prevention)]TJ
2.175 -1.25 Td
[(ef)17.7 (fectiveness. New )36.8 (Y)100 (ork: Oxford University Press; 1996.)]TJ
0 Tc -2.175 -1.25 Td
[(17.)-875 (Y)100.1 (elin E, )17.7 (W)79.8 (anke LA. )54.8 (An assessment of the annual and long-term)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(direct costs of rheumatoid arthritis. )54.8 (Arthritis Rheum 1999; )]TJ
0 Tc 0 Tw T*
(42:1209-18.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic)]TJ
2.175 -1.25 Td
(consequences of the progression of rheumatoid arthritis in Sweden.)Tj
0 Tc T*
(Arthritis Rheum 1999;42:347-56.)Tj
-2.175 -1.25 Td
[(19.)-875 (Y)100.1 (elin E. )17.8 (The costs of rheumatoid arthritis: absolute, incremental,)]TJ
2.175 -1.25 Td
[(and mar)17.8 (ginal estimates. J Rheumatol 1996;23 Suppl 44:47-51.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Lange ML, )17.7 (W)79.7 (ells G, LaV)110.7 (alley MP)110.7 (. Should)]TJ
0 Tc 2.175 -1.25 Td
(improvement in rheumatoid arthritis clinical trials be defined as)Tj
T*
(fifty percent or seventy percent improvement in core set measures,)Tj
T*
[(rather than twenty percent? )54.9 (Arthritis Rheum 1998;41:1564-70.)]TJ
-2.175 -1.25 Td
[(21.)-875 (Pillemer SR, Fowler SE, )17.7 (T)34.9 (illey BC, et al. Meaningful improvement)]TJ
2.175 -1.25 Td
[(criteria sets in a rheumatoid arthritis clinical trial. MIRA)-202.3 (T)34.9 (rial)]TJ
T*
[(Group. Minocycline in rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1997;40:419-25.)Tj
0.0249 Tw -2.175 -1.25 Td
[(22.)-875 (Lipsky PE, van der Heijde DM, St Clair EW)91.8 (, et al. Infliximab and)]TJ
2.175 -1.25 Td
(methotrexate in the treatment of rheumatoid arthritis. N Engl J Med)Tj
0 Tw T*
(2000;343:1594-602.)Tj
0.02499 Tw -2.175 -1.25 Td
[(23.)-875 (Maini R, St Clair EW)91.8 (, Breedveld F)79.8 (, et al. Infliximab \(chimeric anti-)]TJ
2.175 -1.25 Td
(tumour necrosis factor alpha monoclonal antibody\) versus placebo)Tj
T*
(in rheumatoid arthritis patients receiving concomitant methotrexate:)Tj
-0.00011 Tc T*
[(a randomised phase III trial. )54.8 (A)111 (TTRACT)-257.3 (Study Group. Lancet)]TJ
0 Tc 0 Tw T*
(1999;354:1932-9.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Choi, et al: RA)-257.2 (cost effectiveness)]TJ
0 Tw 60.9375 -0.0313 Td
(1165)Tj
ET
0 0 0 0 scn
/GS0 gs
100.25 59.11 407.5 -10.83 re
f*
0.5 w
100.25 59.11 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
100 0 obj
<>
endobj
126 0 obj
<>
endobj
77 0 obj
<>
endobj
67 0 obj
<>
endobj
63 0 obj
<>
endobj
62 0 obj
<>
endobj
90 0 obj
<>stream
HV pUBBr@6d7$$CP`D0 A*%Q*,["d5)ajXe)J-Xȱ~= Vmm|v/fO`zcJ*U;b@Z?u~4u ZVyI{1#P/_!@4_VK\:xҧ_ K**u5@
{eVY;jD^Ux|=h,۾U65ںA
N9eU_ Q,Ҫr |tT*XII׃EVPwH[q`a!oݑGB\z,M!3y8Bdx1)Ȧ_Xx р8|q{8*>Wk5#=~ěXemk5c2G%q?k8rM ZN
"\tD"xz ;M&s9>`(F`^SdRoX^?(2bZ|&eh5Yi+! ]3#w2c62S8qD(Ջ֕N8YɾD>8Y {>nbgΡwpOh)Dw)qVFiaQfԋ7*U`Z/Yegn%L!R^n/b챘c>f|
_r#83*C3n6>QD(hȑ,ܬv5O5bśb1A_d,BL ,[JXjZn"VwFpRpJ&xrZVUc-6XJ=ba#i(Ii(A9f7X͵zf1O,dv3n.#( Tֹ3sŌr/
D"rQ!f渜cxYnD+&۫A2ɕ~J@.ow:,,MCb5A$+9(eWf+MfewҬS+>j:V]QOsu2ZV^ڻZ];usN9ss7o.D}yXzqWYr ߝE'QGyFDlC:D)NY^JpAꂻJFaj Fe5\1U[
xz;=-O$w3~һvIJLݩSGh&Lj1b
?>Sh6OZzhY3KO硥a;]y8EѸWZՔӎEW§{5/w;Mb#/d[xx#kv6rB:%/5xs\Bw)Ki&afVPdәm:ZN ݁QK(5J/f9fVo4epY`8K|D9
r#_S.),0m6$-pcQc&wm4YQ |.($6tB`O;{OjMqX&PP{[2{q!}9jb<,LD' P2f|
De5Ւ=Fړđk3-LMeٟ2І}5fQ ,XGaVr-[42f^Ǵdgkv?Dۚ>qbfXOފ,SuYHok$Ma%
V>RT/}RbrM8ɑu3!'(@%LmO*!Œ$)4)>ug!瀍I
m]uVҺN}=:5vgs1g)C]WJ̍cՖpJꮬ@;(R̄~'rv?1\ԏ&OTu~!%ɺ8}u[>`m L qj"{~3:ד:*aLW3WqtY&3~w~_;puBb7 _`BƉ $B
[2(L %)$-hRG@,,1壬HcTuZ&eb6xϝ`GYz={mb"}m$~ꖰ=-W!,z9%P؎ºIETC|{Qcyl'݃z%
wrdBQ^+X-|>)lǫ@c3H bx;{z$G@}T
A[08,0# 7:I !&c8Gr2G,oY$sr+?ǟLt$ـ, C)#0pXDGptx?~2ɰ:&:WśM' V N 0d K' :uWt`ɏdt^ Q'{ 0d u d1F&.`#KhR&Jm\nSnS-\wsm2#We*\(G8A5[2Ѧ)mJ]M)ic
&Oq:_s(ߴ(oQ>mQFZE)jQtfWn+?W~ff!yO,)0
2~1jEDO!__ |?^&~3^C<¼KG\
Tmh0\x
pYnMƵP#ȫrcIE Y:A:^OQ䔖NxzX'|grÝ'iT]8d.sgcC`wޒ^
)J=*c/Of/BhHA/XHjnkJʽUƲL) "-ΣQnHWQ5ERROmb?bj)L-bR@K69[6˙r&˲Qd¦'JZlF3f4k2A-
N2dr d d?k } @zAv L|q'9Y%S@4@zRac[q5j<